Askofen Plus

Askofen plus

Country of origin: France

Pharm-Group: Combined analgesics-antipyretics

Manufacturers: Natur Product (France)

International name: Acetylsalicylic acid + Paracetamol + Caffeine

Synonyms: Aquacitramon, Algomin, Algon, Askofen-ANVI, Askofen-P, Acifein, Iralgesik, Kofitsil-Plus, Neuranidal, Oldon, Tomapirin, Tsefekon P, Citramon MFF, Citramon P, Citramon P-MIK, Citramon-borimed, Citrapar

Dosage forms: tablets

Ingredients: Acetylsalicylic acid, paracetamol, caffeine.

Indications for use: Pain syndrome of mild and moderate severity: headache and dental pain, neuralgia, arthralgia, myalgia, dysmenorrhea, etc.; fever due to colds and other infectious and inflammatory diseases.

Contraindications: Hypersensitivity, gastric and duodenal ulcers, gastrointestinal bleeding, severe liver and kidney dysfunction, hypocoagulation, genetically determined deficiency of glucose-6-phosphate dehydrogenase, glaucoma, bronchial asthma, first trimester of pregnancy, breastfeeding.

Side effects: From the gastrointestinal tract: pain in the stomach, nausea; impaired liver function, erosive and ulcerative lesions of the gastrointestinal tract (with long-term use of high doses). Other: palpitations, bronchospasm, renal dysfunction.

Interaction: Strengthens the effect of anticoagulants and antiplatelet agents, side effects, etc. NSAIDs and non-narcotic analgesics, glucocorticoids, sulfonamides, methotrexate. Should not be combined with barbiturates, anticonvulsants, rifampicin, alcohol.

Overdose: Symptoms: stomach pain, nausea, vomiting, sweating, pale skin, tachycardia. Treatment: gastric lavage using activated carbon, symptomatic therapy.

Special instructions: Not prescribed to children under 15 years of age against the background of acute respiratory viral infection or influenza (possible development of Reye's syndrome). Prescribe with caution in old age, with impaired liver or kidney function. Should not be taken for more than 5 days as an analgesic and 3 days as an antipyretic without the advice and supervision of a physician.

Literature:

1. Register of Medicines 2003.